The Patent Finder

Ophthalmic Formulations of Methotrexate

Aldeyra Therapeutics, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 3 of these applications claim priority to application PCT/US2020/050565, filed Sep 11, 2020. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 12,005,060Ophthalmic Formulations of Methotrexate
In force
 · Medium confidence
UsedRemaining
Aldeyra Therapeutics, Inc.In forceMedium confidence
US 12,005,061Ophthalmic Formulations of Methotrexate
In force
 · Medium confidence
Aldeyra Therapeutics, Inc.In forceMedium confidence
US 12,616,699Ophthalmic Formulations of Methotrexate
In force
 · Medium confidence
Aldeyra Therapeutics, Inc.In forceMedium confidence
Application 19/643,612Ophthalmic Formulations of Methotrexate
Pending
Not granted
Aldeyra Therapeutics, Inc.PendingNot granted
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Aldeyra Therapeutics, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited